Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2015

View Archived Issues

Otsuka Pharmaceutical profiles progress of second quarter 2015

Genetic factors modify clinical onset of Huntington's disease

AbbVie and Reata present NO production inhibitors

Nabriva divulges mutilin derivatives

Confluence Life Sciences patents ITK inhibitors

Millenium presents PIK3C3 inhibitors

Cardioxyl Pharmaceuticals patents HNO donors

Phase I study investigates ADCT-301 for relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

Allogenic MPCs show safety in HF patients

Immune Design and Merck & Co. collaborate to study immunotherapies with Keytruda

Gamida Cell reaches agreements on phase III trial design for NiCord

Relypsa signs new patiromer agreements

Novavax reports phase II results for RSV vaccine in older adults

EEC announced between Intrexon and Synthetic Biologics

Galapagos reports 24-week data from the phase IIb DARWIN 2 trial

Adynxx reports positive results for phase IIb study of AYX-1

Editas Medicine raises funds to advance genome editing platform

Intrexon to acquire insect control solutions company Oxitec

Mallinckrodt to acquire photopheresis company Therakos

FDA accepts La Jolla's IND for phase I study of LJPC-401

InSite Vision receives second acquisition offer, following agreement with QLT

IL-1alpha blockade shows promise for the treatment of type 2 diabetes

DSMB recommends continuation of phase I trial of ContraFect's CF-301

Janssen Biotech enters license agreement for Alligator's ADC-1013

Janssen starts phase III trial of ustekinumab in non-radiographic axial spondyloarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...